Key facts
- 01life’s last known valuation is $181.8M (Apr 2023).
- It has raised $14.5M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Green Pine Capital Partners, Empower Investment, Beyond Ventures, Danen Capital, Resources Investment — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for 01life
- ·The full record, as it builds
Funding rounds
No funding rounds for 01life are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 01life
Developer of gut microorganisms drugs designed for disease prevention and treatment. The company develops original new drug pipelines, genetic testing products, and probiotics+ products based on its complete life-cycle micro-ecological health management services with periodic examination and intervention, enabling customers with innovative human flora genetic testing products for more visibility into microecological health.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2016
- Employees
- 20
- Website
- indiv.cn/
- Ownership
- Privately Held (backing)
01life doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 01life shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 01life in its N-PORT filings yet. We sweep new filings monthly.